Asset: Novel Claudin6-targeted ADC armed with optimized TOPO1 inhibitor payload
Development Stage: Clinical stage
Indication: Ovarian Cancer and Non-Small Cell Lung Cancer (NSCLC)
Key Asset Highlights:
（1）Represents a mono-targeting Claudin6 ADC featuring a validated and clinically optimized TOPO1 inhibitor payload, rationally designed to overcome the inherent limitations of existing clinical comparator ADCs.
（2）Exerts precise tumor-targeting delivery by specifically binding to Claudin6, a tumor-specific tight junction protein highly overexpressed in ovarian cancer and NSCLC, achieving accurate enrichment at tumor lesions while minimizing off-tumor exposure.
（3）The conjugated TOPO1 inhibitor payload effectively induces tumor DNA damage and inhibits DNA replication, triggering potent cytotoxicity and robust anti-tumor responses against Claudin6-positive malignant cells.
（4）Demonstrates prominent differentiated performance over conventional Claudin6 ADC candidates, with optimized payload properties and linker design to enhance therapeutic window and reduce treatment-related toxicities.
（5）Delivers robust and durable preclinical anti-tumor efficacy in multiple solid tumor models, possessing high clinical translatability and reliable safety profiles to support sustainable clinical success.
（6）Protected by a comprehensive global intellectual property portfolio, securing exclusive and stable worldwide development and commercialization rights for Claudin6-positive solid tumor indications.
If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.
Email: BD@drugtimes.cn
Thank you very much!
【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.
发布者：DrugTimes001，转载请首先联系contact@drugtimes.cn获得授权
为好文打赏 支持药时代 共创新未来！ 
